Understanding hereditary kidney stone diseases
Prospective Research Rare Kidney Stones (ProRKS)
This study is trying to learn more about hereditary kidney stone diseases and how they affect kidney health over time by looking at patients' blood and urine samples.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 220 (estimated) |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 11 sites (Birmingham, Alabama and 10 other locations) |
| Trial ID | NCT02780297 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the natural history of hereditary forms of kidney stones and chronic kidney disease, including conditions like primary hyperoxaluria, cystinuria, Dent disease, and adenine phosphoribosyltransferase deficiency. Researchers will collect longitudinal data on patients, measuring blood and urinary markers of inflammation to explore their relationship with disease progression. By cross-comparing these disorders, the study seeks to identify factors that influence disease severity and kidney injury, ultimately enhancing understanding of renal dysfunction mechanisms.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with primary hyperoxaluria, enteric hyperoxaluria, Dent disease, cystinuria, adenine phosphoribosyltransferase deficiency, or Lowe Syndrome.
Not a fit: Patients with prior renal failure or those who have undergone liver and/or kidney transplants may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment strategies for patients with hereditary kidney stone diseases.
How similar studies have performed: Other studies have shown success in understanding kidney stone diseases, but this specific approach focusing on hereditary forms is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Diagnosis of primary hyperoxaluria 2. Diagnosis of enteric hyperoxaluria 3. Diagnosis of Dent Disease 4. Diagnosis of Cystinuria 5. Diagnosis of adenine phosphoribosyltransferase deficiency (APRTd) 6. Diagnosis of Lowe Syndrome 7. Diagnosis of Dent Disease Carrier Exclusion Criteria: 1. Prior renal failure 2. History of liver and/or kidney transplant.
Where this trial is running
Birmingham, Alabama and 10 other locations
- University of Alabama @ Birmingham — Birmingham, Alabama, United States (Not_yet_recruiting)
- Mayo Clinic Jacksonville — Jacksonville, Florida, United States (Not_yet_recruiting)
- Children's Memorial Hospital — Chicago, Illinois, United States (Not_yet_recruiting)
- Children's Hospital, Harvard Medical School — Boston, Massachusetts, United States (Not_yet_recruiting)
- Mayo Clinic Hyperoxaluria Center — Rochester, Minnesota, United States (Recruiting)
- New York University — New York, New York, United States (Not_yet_recruiting)
- Cincinnati Children's Hosptial Medical Center — Cincinnati, Ohio, United States (Not_yet_recruiting)
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States (Not_yet_recruiting)
- Hosptial of Sick Children — Toronto, Ontario, Canada (Not_yet_recruiting)
- Landspitali Universtiy Hospital — Reykjavik, Iceland (Not_yet_recruiting)
- Shaare Zedek Medica Center — Jerusalem, Israel (Not_yet_recruiting)
Study contacts
- Principal investigator: John Lieske, MD — Mayo Clinic
- Study coordinator: Barb Seide
- Email: RareKidneyStones@mayo.edu
- Phone: 800-270-4637
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.